Jacques Kpodonu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacques Kpodonu has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Monica Ahluwalia
Director, Inherited Cardiac Diseases Program, Division of Cardiovascular Medicine, Boston Medical Center; Attending Physician, Boston Medical Center and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
5 shared publicationsRalf Martz Sulague
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
5 shared publicationsEmmanuel Agu
Department of Computer Science, Worcester Polytechnic Institute, Worcester, MA, USA
4 shared publications- Ana Olga Mocumbi
Universidade Eduardo Mondlane, Campus Universitário, Maputo, Mozambique
3 shared publications - Abdulsalam Almadani
Worcester Polytechnic Institute, Worcester, MA, USA
2 shared publications - Amy Sanyahumbi
Division of Cardiology, Department of Pediatrics, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX
2 shared publications
Latest Publications
- Open Access
HCM-PhenotypeNet: Deep Multimodal Phenotyping of Hypertrophic Cardiomyopathy from Echocardiographic Video and Clinical Data
Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with variable morphology and symptoms, leading to adverse outcomes such as atrial fibrillation, heart failure and sudden cardiac death. Data-driven phenotyping may help refine risk stratification and guide management. Objectives: To propose an automated machine learning framework ( HCM-PhenotypeNet ) that integrates echocardiographic video and clinical data to identify clinically meaningful HCM phenotypes. Methods: We developed a multimodal pipeline using a deep neural network to extract features from 1,553 echocardiography video clips, combined with > 100 clinical variables from 156 HCM patients. Patient-level vectors were reduced using UMAP and clustered using Deep Embedded Clustering (DEC). Cluster quality was assessed using internal validation metrics, and clusters were characterized through statistical comparisons and association rule mining. Results: The cohort included 156 HCM patients (mean age 53.6 ± 13.9 years, 40.4% female) with pre-served systolic function and diverse racial/ethnic backgrounds. The optimal pipeline (DEC with 4 clusters) yielded phenogroups with strong separation (silhouette ≈ 0.89): (A) Advanced Obstructive/Metabolic phenotype; (B) Early-onset, Genotype Positive phenotype; (C) Late-onset, mild non-obstructive phenotype; and (D) Hypertrophic Heart Failure-predominant phenotype. Whilst there was no mortality difference, there was a trend towards increased heart failure and atrial fibrillation burden in the Advanced Obstructive/Metabolic and Heart Failure-predominant subgroups. Conclusions: HCM-PhenotypeNet enabled automated identification of four clinically relevant HCM subgroups. These phenogroups highlight the heterogeneity of HCM and may support personalized risk stratification and management but require validation in larger cohorts.
Open AccessHCM-PhenotypeNet: Deep Multimodal Phenotyping of Hypertrophic Cardiomyopathy from Echocardiographic Video and Clinical Data
Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with variable morphology and symptoms, leading to adverse outcomes such as atrial fibrillation, heart failure and sudden cardiac death. Data-driven phenotyping may help refine risk stratification and guide management. Objectives: To propose an automated machine learning framework ( HCM-PhenotypeNet ) that integrates echocardiographic video and clinical data to identify clinically meaningful HCM phenotypes. Methods: We developed a multimodal pipeline using a deep neural network to extract features from 1,553 echocardiography video clips, combined with > 100 clinical variables from 156 HCM patients. Patient-level vectors were reduced using UMAP and clustered using Deep Embedded Clustering (DEC). Cluster quality was assessed using internal validation metrics, and clusters were characterized through statistical comparisons and association rule mining. Results: The cohort included 156 HCM patients (mean age 53.6 ± 13.9 years, 40.4% female) with pre-served systolic function and diverse racial/ethnic backgrounds. The optimal pipeline (DEC with 4 clusters) yielded phenogroups with strong separation (silhouette ≈ 0.89): (A) Advanced Obstructive/Metabolic phenotype; (B) Early-onset, Genotype Positive phenotype; (C) Late-onset, mild non-obstructive phenotype; and (D) Hypertrophic Heart Failure-predominant phenotype. Whilst there was no mortality difference, there was a trend towards increased heart failure and atrial fibrillation burden in the Advanced Obstructive/Metabolic and Heart Failure-predominant subgroups. Conclusions: HCM-PhenotypeNet enabled automated identification of four clinically relevant HCM subgroups. These phenogroups highlight the heterogeneity of HCM and may support personalized risk stratification and management but require validation in larger cohorts.
- 2 September 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 933
Hospital costs and procedural learning curves of robotic mitral valve surgery: a systematic review and meta-analysis
- 2 September 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 933
Hospital costs and procedural learning curves of robotic mitral valve surgery: a systematic review and meta-analysis
- Open Access
- 6 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Design and operational feasibility of an AI-enabled, physician-led clinical judgment layer for healthcare navigation platform (Preprint)
BACKGROUND Patients frequently report difficulty understanding diagnoses, treatment options, and recommended next steps within fragmented healthcare systems, contributing to anxiety, decisional conflict, and incomplete follow-through.¹,² Time-limited encounters, increasing diagnostic complexity, and care across multiple settings further challenge patient comprehension and engagement. While AI-enabled digital health tools have expanded access to medical information, many systems function primarily as information delivery or automation tools and lack explicit mechanisms for physician-led clinical judgment or integration of patient-specific records.³,⁴ Advances in artificial intelligence support medical document aggregation and organization,⁵ yet unclear delineation between algorithmic processing and physician accountability has raised concerns regarding safety, trust, and clinical responsibility.⁶,⁸ OBJECTIVE To assess the design, implementation, and operational feasibility of an AI-enabled healthcare navigation platform structured to separate AI-based information aggregation from physician-led clinical judgment, interpretation, and patient guidance in real-world use. METHODS We conducted a prospective pilot service evaluation of an AI-enabled, physician-led healthcare navigation platform. Fifty participants completed at least one structured navigation encounter over three months. AI components were limited to aggregation, organization, and summarization of medical records, while licensed physicians provided all interpretation, recommendations, and guidance.⁹,¹⁰ Outcomes were analyzed descriptively to characterize feasibility-relevant signals, including utilization, workflow completion, patient-reported clarity and decision confidence, follow-through on physician-recommended actions, patient experience measures, and qualitative feedback, without hypothesis testing or causal attribution. RESULTS Utilization patterns reflected sustained engagement and acceptable data completeness for feasibility assessment. Mean patient-reported clarity scores were higher following navigation (8.3, SD 1.0) compared with pre-navigation assessment (3.6, SD 1.4). Observed score differences were broadly distributed across participants. Engagement included repeated navigation encounters and medical document review. Physician-recommended follow-through actions were common, with timely completion reported. Patient experience ratings indicated acceptability of the physician-led model. CONCLUSIONS This pilot evaluation provides descriptive evidence supporting the implementation feasibility of an AI-enabled, physician-led clinical judgment layer for healthcare navigation. Observed signals reflect system use and workflow execution rather than clinical effectiveness and inform the design of future controlled evaluations.¹¹ CLINICALTRIAL This work was conducted as a prospective pilot service evaluation and was not registered as a clinical trial.¹¹
- 6 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDesign and operational feasibility of an AI-enabled, physician-led clinical judgment layer for healthcare navigation platform (Preprint)
BACKGROUND Patients frequently report difficulty understanding diagnoses, treatment options, and recommended next steps within fragmented healthcare systems, contributing to anxiety, decisional conflict, and incomplete follow-through.¹,² Time-limited encounters, increasing diagnostic complexity, and care across multiple settings further challenge patient comprehension and engagement. While AI-enabled digital health tools have expanded access to medical information, many systems function primarily as information delivery or automation tools and lack explicit mechanisms for physician-led clinical judgment or integration of patient-specific records.³,⁴ Advances in artificial intelligence support medical document aggregation and organization,⁵ yet unclear delineation between algorithmic processing and physician accountability has raised concerns regarding safety, trust, and clinical responsibility.⁶,⁸ OBJECTIVE To assess the design, implementation, and operational feasibility of an AI-enabled healthcare navigation platform structured to separate AI-based information aggregation from physician-led clinical judgment, interpretation, and patient guidance in real-world use. METHODS We conducted a prospective pilot service evaluation of an AI-enabled, physician-led healthcare navigation platform. Fifty participants completed at least one structured navigation encounter over three months. AI components were limited to aggregation, organization, and summarization of medical records, while licensed physicians provided all interpretation, recommendations, and guidance.⁹,¹⁰ Outcomes were analyzed descriptively to characterize feasibility-relevant signals, including utilization, workflow completion, patient-reported clarity and decision confidence, follow-through on physician-recommended actions, patient experience measures, and qualitative feedback, without hypothesis testing or causal attribution. RESULTS Utilization patterns reflected sustained engagement and acceptable data completeness for feasibility assessment. Mean patient-reported clarity scores were higher following navigation (8.3, SD 1.0) compared with pre-navigation assessment (3.6, SD 1.4). Observed score differences were broadly distributed across participants. Engagement included repeated navigation encounters and medical document review. Physician-recommended follow-through actions were common, with timely completion reported. Patient experience ratings indicated acceptability of the physician-led model. CONCLUSIONS This pilot evaluation provides descriptive evidence supporting the implementation feasibility of an AI-enabled, physician-led clinical judgment layer for healthcare navigation. Observed signals reflect system use and workflow execution rather than clinical effectiveness and inform the design of future controlled evaluations.¹¹ CLINICALTRIAL This work was conducted as a prospective pilot service evaluation and was not registered as a clinical trial.¹¹
- Open Access
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101742
Disparities in Artificial Intelligence–Based Tools Among Diverse Minority Populations
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101742
Open AccessDisparities in Artificial Intelligence–Based Tools Among Diverse Minority Populations
- Open Access
- 9 December 2024
- Published by Elsevier in JACC: Advances
- Vol. 4 (1) , 101412
Optimal Medical Therapy Versus Septal Reduction Therapy
- 9 December 2024
- Published by Elsevier in JACC: Advances
- Vol. 4 (1) , 101412
Open AccessOptimal Medical Therapy Versus Septal Reduction Therapy
- Open Access
- 31 October 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101347
Rheumatic Heart Disease Burden in Africa and the Need to Build Robust Infrastructure
- 31 October 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101347
Open AccessRheumatic Heart Disease Burden in Africa and the Need to Build Robust Infrastructure
- Open Access
- 25 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 6, 193-201
HCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms
Goal: To detect Hypertrophic Cardiomyopathy (HCM) from multiple views of Echocardiogram (cardiac ultrasound) videos. Methods: we propose HCM-Echo-VAR-Ensemble, a novel framework that performs binary classification (HCM vs. no HCM) of echocardiogram videos directly using an ensemble of state-of-the-art deep VAR architectures models (SlowFast and I3D), and fuses their predictions using majority averaging ensembling. Results: HCM-Echo-VAR-Ensemble achieved state-of-the-art accuracy of 95.28%, an F1-Score of 95.20%, a specificity of 96.20%, a sensitivity of 93.97%, a PPV of 96.46%, an NPV of 94.17%, and an AUC of 98.42%, outperforming a comprehensive set of baselines including other ensembling approaches. Conclusions: Our proposed HCM-Echo-VAR-Ensemble framework demonstrates significant potential for improving the sensitivity and accuracy of HCM detection in clinical settings, particularly by ensembling the complementary strengths of the SlowFast and I3D deep VAR models. This approach can enhance diagnostic consistency and accuracy, enabling reliable HCM diagnoses even in low-resource environments.
- 25 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 6, 193-201
Open AccessHCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms
Goal: To detect Hypertrophic Cardiomyopathy (HCM) from multiple views of Echocardiogram (cardiac ultrasound) videos. Methods: we propose HCM-Echo-VAR-Ensemble, a novel framework that performs binary classification (HCM vs. no HCM) of echocardiogram videos directly using an ensemble of state-of-the-art deep VAR architectures models (SlowFast and I3D), and fuses their predictions using majority averaging ensembling. Results: HCM-Echo-VAR-Ensemble achieved state-of-the-art accuracy of 95.28%, an F1-Score of 95.20%, a specificity of 96.20%, a sensitivity of 93.97%, a PPV of 96.46%, an NPV of 94.17%, and an AUC of 98.42%, outperforming a comprehensive set of baselines including other ensembling approaches. Conclusions: Our proposed HCM-Echo-VAR-Ensemble framework demonstrates significant potential for improving the sensitivity and accuracy of HCM detection in clinical settings, particularly by ensembling the complementary strengths of the SlowFast and I3D deep VAR models. This approach can enhance diagnostic consistency and accuracy, enabling reliable HCM diagnoses even in low-resource environments.
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Shanghai Chest
- Vol. 8, 20
Cardiac myosin inhibitors in hypertrophic cardiomyopathy: gaps in knowledge and future opportunities
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease affecting 1:200 to 1:500 individuals. It is characterized by a complex interplay of factors including increased septal wall thickness, small ventricular size, left ventricular outflow tract (LVOT) obstruction, mitral valve abnormalities, myocardial hypercontractility, and diastolic dysfunction. Despite therapeutic advancements, critical knowledge gaps persist particularly concerning the use of cardiac myosin inhibitors. This review aimed to consolidate existing knowledge, identify these gaps, and delineate the directions for future research in HCM management. Our comprehensive literature search, spanning PubMed/MEDLINE and Google Scholar, explored HCM, cardiac surgery, and myosin inhibitors. Studies unveiled the potential of β-cardiac myosin ATPase inhibitors to improve symptoms, LVOT gradients, and overall health in HCM patients. Drops in left ventricular ejection fraction associated with these medications may be addressed by proper dose adjustments or discontinuation. While long-term data are further needed, initial studies point to their cost-effectiveness. Notably, minority ethnic groups and women continue to be underrepresented in clinical trials and experience disproportionately higher cardiovascular mortality. Global collaboration, comprehensive registries, and data-sharing initiatives are key to advancing HCM research and improving patient outcomes. Future research must prioritize the inclusivity and diversity of ethnic minority groups to improve the applicability of conclusions and comprehensively advance HCM management.
- 1 October 2024
- Published by AME Publishing Company in Shanghai Chest
- Vol. 8, 20
Open AccessCardiac myosin inhibitors in hypertrophic cardiomyopathy: gaps in knowledge and future opportunities
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease affecting 1:200 to 1:500 individuals. It is characterized by a complex interplay of factors including increased septal wall thickness, small ventricular size, left ventricular outflow tract (LVOT) obstruction, mitral valve abnormalities, myocardial hypercontractility, and diastolic dysfunction. Despite therapeutic advancements, critical knowledge gaps persist particularly concerning the use of cardiac myosin inhibitors. This review aimed to consolidate existing knowledge, identify these gaps, and delineate the directions for future research in HCM management. Our comprehensive literature search, spanning PubMed/MEDLINE and Google Scholar, explored HCM, cardiac surgery, and myosin inhibitors. Studies unveiled the potential of β-cardiac myosin ATPase inhibitors to improve symptoms, LVOT gradients, and overall health in HCM patients. Drops in left ventricular ejection fraction associated with these medications may be addressed by proper dose adjustments or discontinuation. While long-term data are further needed, initial studies point to their cost-effectiveness. Notably, minority ethnic groups and women continue to be underrepresented in clinical trials and experience disproportionately higher cardiovascular mortality. Global collaboration, comprehensive registries, and data-sharing initiatives are key to advancing HCM research and improving patient outcomes. Future research must prioritize the inclusivity and diversity of ethnic minority groups to improve the applicability of conclusions and comprehensively advance HCM management.
- Open Access
- 25 September 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101196
Echocardiogram Vector Embeddings Via R3D Transformer for the Advancement of Automated Echocardiography
- 25 September 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101196
Open AccessEchocardiogram Vector Embeddings Via R3D Transformer for the Advancement of Automated Echocardiography
- Open Access
- 26 June 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 54
Correction: Decentralization and Integration of Advanced Cardiac Care for the World’s Poorest Billion Through the PEN-Plus Strategy for Severe Chronic Non-Communicable Disease
Global Heart is the official and primary publication of the World Heart Federation, offering a platform for the dissemination of knowledge on research, developments, trends, solutions and public health programmes in the area of cardiovascular disease. Global Heart welcomes research results, points of view and educational material on the prevention, treatment and control of cardiovascular disease with a special focus on low and middle-income countries which are facing the brunt of epidemiological transition.Global Heart strongly encourages authors to adhere to CONSORT, STROBE, STARD, and PRISMA guidelines for reporting of clinical trials, observational studies, diagnostic test accuracy papers, and systematic reviews or meta-analyses. Authors are required for submission to download and complete the appropriate Equator Network checklist: http://www.equator-network.org/.
- 26 June 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 54
Open AccessCorrection: Decentralization and Integration of Advanced Cardiac Care for the World’s Poorest Billion Through the PEN-Plus Strategy for Severe Chronic Non-Communicable Disease
Global Heart is the official and primary publication of the World Heart Federation, offering a platform for the dissemination of knowledge on research, developments, trends, solutions and public health programmes in the area of cardiovascular disease. Global Heart welcomes research results, points of view and educational material on the prevention, treatment and control of cardiovascular disease with a special focus on low and middle-income countries which are facing the brunt of epidemiological transition.Global Heart strongly encourages authors to adhere to CONSORT, STROBE, STARD, and PRISMA guidelines for reporting of clinical trials, observational studies, diagnostic test accuracy papers, and systematic reviews or meta-analyses. Authors are required for submission to download and complete the appropriate Equator Network checklist: http://www.equator-network.org/.